FDA Approved: HADLIMA — Supplemental Application (Organon LLC)

View source ↗

Summary

FDA approved a supplemental application for HADLIMA (adalimumab-bwwd) from Organon LLC, supporting expanded indications for this adalimumab biosimilar.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• HADLIMA (ADALIMUMAB-BWWD)

Snippet

SUPPL AP for HADLIMA (ADALIMUMAB-BWWD)